leisure time -WSS

leisure time

author：comprehensive 2025-09-03 03:31:04 - browse：35

Dallas Mavericks owner Mark Cuban reacts during a timeout in the game against the Golden State Warriors at American Airlines Center on March 22, 2023 in Dallas, Texas. – opinion coverage from STAT — Tim Heitman/Getty Images

Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his direct-to-consumer venture, Cost Plus Drugs. The company sells generic prescription drugs and boasts more than 2 million members. As a family medicine specialist who has firsthand experience with American households’ dissatisfaction with the state of the nation’s prescription drug marketplace, I believe the enthusiasm for Cost Plus Drugs reveals an appetite for alternatives to the status quo in the pharmaceutical industry.

Cuban claims the reason behind the success of Cost Plus Drugs is the company’s decision to bypass pharmaceutical benefit managers — the negotiating agents insurance companies hire to negotiate big pharma’s prices down. But that might not be the case. Instead, its success appears to lie in its choice to collaborate with affordable generic drug manufacturers rather than the major pharmaceutical companies.

Last year, the Department of Health and Human Services found that between July 2021 and July 2022, major pharma companies raised the list price on more than 1,200 drugs by an average of 31 percent. That’s 23 percent more than the country’s overall inflation rate during the same period. Meanwhile, generic drug companies saved the U.S. roughly $2.6 trillion from 2012 to 2021, according to the Association for Accessible Medicines, a trade group representing generic drug manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： A disappointing year of Humira biosimilars

knowledge

WSS

NIH chief: government has fallen behind pharma on clinical trials

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Type 2 diabetes prevention programs work at large scale: study

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Healthy food access boosts outcomes in two studies

Medicare threatens to cut off funding for HCA's Mission hospital

entertainment

leisure time

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

BioAge raises $170M for combination therapy with Zepbound

As demand for Covid shots wanes, Moderna seeks its next success

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Guidelines to prevent youth baseball injuries need more muscle

Vaccine advisory panel ACIP left half staffed by HHS

Heart attack and stroke risk calculators need revising

To avoid data mishandling cases, universities eye AI and other tools

As demand for Covid shots wanes, Moderna seeks its next success

How state and local governments are sidelining science

focus

Carbon Health diabetes program, a test of data

Medical school prerequisites are outdated

Medicare Advantage proposed rates disappoint insurers

Publishing genetic code of viruses could cause disaster

Robert F. Kennedy is pitching centrism on health, even on abortion

Ohio still needs to do more to protect the right to abortion

hotspot

knowledge

knowledge

leisure time